Insys Therapeutics price target raised to $99 from $50 at JMP Securities JMP Securities increased its price target on Insys after the company reported higher than expected earnings. The firm expects the company to benefit from continued growth in its Subsys drug and further advances in its pipeline. JMP Securities reiterates an Outperform rating on the stock.
News For INSY From The Last 14 Days
Check below for free stories on INSY the last two weeks.